Published on
September 29, 2025
- 13:50 GMT
VRise Therapeutics Secure Exclusive License for KQ-2003 world's first parallel-enhanced dual-targeted CAR-T in India
KQ-2003 is a clinically validated first-in-class Dual BCMA-CD19 CAR-T, with demonstrated best-in-class responses in patients with r/r MM and POEMS syndrome CAMBRIDGE, MA, UNITED STATES, September 29, 2025 /EINPresswire.com/ -- VRise Therapeutics Inc. (“ …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
